Jiqiang Lin

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Flare Therapeutics, a clinical-stage biotechnology company, on its strategic discovery collaboration with Roche.

Cooley advised Foreseen Biotechnology – an emerging biotech company that pioneered a high-throughput integrated translational proteomics platform powered by an artificial intelligence-based data analytical system to accelerate the discovery of novel targets for therapeutics and diagnostics that are clinically relevant – on its exclusive global licensing agreement with Ipsen for FS001, an antibody-drug conjugate with first-in-class potential.

Cooley advised Ochre Bio, a UK-based pioneer in chronic liver disease medicine development with labs in New York and Taipei, on its partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.